Onyia Jude's Form 4 filing
Neurocrine Biosciences Inc (NBIX) · filed Sep 15, 2026
- Accession no.
- 0001894425-26-000020
- Filed
- Sep 15, 2026, 5:07 PM ET
- Trade date
- Sep 11, 2026
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Onyia JudeCIK 0001894425 | Officer (Chief Scientific Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 11, 2026 | Common Stock | AGrant or awardAcquired | +3,587 | $0.00 | $0 | 24,583 | Direct | |
| Sep 11, 2026 | Common Stock | FTax withholdingDisposed | −1,936 | $156.22 | −$302,441.92 | 22,647 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.